PPT-Telaprevir BID versus q8 in Treatment Naïve GT-1

OPTIMIZE Study C211 Phase 3 Treatment Naïve Buti M et al Gastroenterology 2013 Dec 4 Epub ahead of print Source Buti M et al Gastroenterology 2013 Dec 4 Epub. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 2. – Important Hepatitis C Protease Inhibitor Drug Interactions in Mono and HIV . Out With the Old, In With the New. Current Standard of Care. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. COMPLETE SLIDE DECK (Chapters 1 – 6). November 2012. Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . Naïve GT-1. ADVANCE (Study 108). Phase . 3. Treatment. . Naïve. Jacobson IM, et. al. N . Engl. J Med. 2011;364:2405-16. .. Source: Jacobson . IM, et. al. . N . Engl. J Med. 2011;364:2405-16.. Telaprevir for Treatment-Naïve HCV Genotype . Naïve GT-1. ILLUMINATE (Study 111). Phase . 3. Treatment. . Naïve. Sherman KE, et. al. N . Engl. J Med. 2011;365:1014-24.. Source: Sherman . KE, et. al. . N . Engl. J Med. 2011;365:1014-24.. Telaprevir for Treatment-Naïve HCV Genotype . BID versus q8 in Treatment Naïve GT-1. OPTIMIZE (. Study . C211). Phase . 3. Treatment. . Naïve. Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Epub. ahead of print]. Source: . Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Regina . Ubaldi. -Rosen, CRNP. ELLAH NOTA, CRNP. GUIDANCE FOR HCV/HIV Co-infection Programs. AIDS CARE GROUP. Is a . non-profit organization that provides medical care, dental care, and social services to uninsured and underinsured minority residents of Chester, Delaware County, . . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. Créteil, France. Paris, 30 January 2012. Triple therapy today:. Safety management in clinical practice. Telaprevir. placebo-controlled Phase II/III studies: . summary of AEs during . telaprevir. /placebo phase. really necessary?. Peter . Ferenci. Medical University of Vienna. Treatment . of. . chronic. non-. A,non. -B . hepatitis. . with. . recombinant. human . alpha. . interferon. . A . preliminary. in Hepatitis C . Paris . Februari. 2012. Ola . Weiland. Karolinska Institutet. Stockholm, Sweden. New major adverse events with PIs. . Exanthema for TVR. . Prolonged anemia with BOC. Telaprevir. Illuminate study.